Beijing, Aug 25, 2026 — China’s Center for Medical Device Evaluation (CMDE) unveiled the 14th batch of innovative medical device special review applications for 2026, clearing 11 products for an expedited regulatory pathway spanning advanced oncology therapy, cardiovascular implants, and brain-computer interfaces.
Regulatory Snapshot
| Attribute | Detail |
|---|---|
| Issuer | Center for Medical Device Evaluation (CMDE), National Medical Products Administration |
| Document | Announcement of Review Results for Special Review Applications of Innovative Medical Devices (No. 14, 2026) |
| Legal basis | NMPA Announcement [2018] No. 83 (Special Review Procedure for Innovative Medical Devices) |
| Products cleared | 11 |
| Public comment period | Aug 25, 2026 – Sept 8, 2026 |
| Contact | gcdivision@cmde.org.cn |
Products Entering Special Review
The 11 devices span therapeutic areas from oncology to neurology:
| No. | Product | Applicant | Category |
|---|---|---|---|
| 1 | Disposable Steep-Pulse Ablation Electrode Needle | Hunan Eweid Medical Device Co., Ltd. | Tumor ablation |
| 2 | Aortic Root Patch | Beijing Balance Medical Technology Co., Ltd. | Cardiovascular surgery |
| 3 | Aortic Valve Replacement System | Shenzhen Jianxin Medical Technology Co., Ltd. | Structural heart |
| 4 | Boron Neutron Capture Therapy System | Huapeng Boron Neutron Technology (Hangzhou) Co., Ltd. | Radiation oncology |
| 5 | Bioresorbable Left Atrial Appendage Occluder | Shanghai Shape Memory Alloy Material Co., Ltd. | Interventional cardiology |
| 6 | Artificial Corneal Endothelial Membrane Patch | Aiyan Medical Co., Ltd. | Ophthalmology |
| 7 | Implantable Brain-Computer Interface Neurostimulator | Beijing PINS Medical Equipment Co., Ltd. | Neurology / neurotechnology |
| 8 | Implantable Tibial Nerve Stimulation System | Hangzhou Shenluo Medical Technology Co., Ltd. | Neuromodulation |
| 9 | Human Circulating Tumor Molecular Residual Disease Detection Kit (CPA Sequencing) | Guangzhou Burning Rock Medical Laboratory Co., Ltd. | Oncology diagnostics |
| 10 | Focused Ultrasound Neuromodulation Device | Chongqing Haifu Medical Technology Co., Ltd. | Therapeutic ultrasound |
| 11 | Absorbable Dural Sealant Glue | Shandong Junxiu Biotechnology Co., Ltd. | Neurosurgery |
Market Impact Analysis
The 14th batch highlights Beijing’s continued prioritization of high-risk, high-innovation devices that address unmet clinical needs. Notable entries include Huapeng Boron Neutron Technology’s boron neutron capture therapy (BNCT) system—a cutting-edge radiation modality for refractory cancers—and Beijing PINS Medical’s implantable brain-computer interface neurostimulator, reflecting China’s strategic push into neurotechnology and advanced neuromodulation.
Cardiovascular devices dominate the roster with three entries, including an aortic valve replacement system and a bioresorbable left atrial appendage occluder, signaling sustained investor and regulatory interest in structural heart interventions. The inclusion of an artificial corneal endothelial membrane patch and an absorbable dural sealant glue underscores expansion into specialized surgical niches with limited existing treatment options.
Burning Rock’s circulating tumor molecular residual disease (MRD) detection kit, using combined probe anchor polymerization sequencing, positions the company to compete in the rapidly growing minimal residual disease monitoring market, a segment increasingly valued for post-surgical cancer recurrence surveillance.
Regulatory Caveats
CMDE emphasized that the public announcement does not constitute formal admission into the special review procedure; final eligibility depends on conclusive review outcomes. Entry into the special review track does not equate to regulatory confirmation of safety or efficacy. Applicants must continue development and submit formal registration applications, which will be evaluated under early engagement, dedicated reviewer, and scientific review principles—without reduced standards or abbreviated procedures.
Forward-Looking Statement
Industry analysts expect the 11 devices to benefit from expedited CMDE review timelines, typically compressing standard approval cycles by 30% to 50% for innovative products. The batch’s diversity—from BNCT systems to brain-computer interfaces—suggests regulators are casting a wide net for breakthrough technologies rather than concentrating on a single therapeutic area. Companies with pipeline candidates in neuromodulation, advanced radiation therapy, and molecular diagnostics should view the special review pathway as increasingly accessible, though the caveat on unchanged evidentiary standards means clinical trial requirements remain rigorous. Final special review determinations are expected by late September 2026, barring substantive objections during the two-week comment window.-China Health Reform Pulse
Policy Source: https://www.cmde.org.cn/xwdt/zxyw/20260825110558111.html